Yu-NingWongMD

Oncology • Philadelphia, PA

Program Director, Genitourinary Medical Oncology Associate Professor, Department of Hematology/Oncology at Fox Chase

Join to view full profile

Dr. Wong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wong's full profile

Already have an account?

Office
3400 Spruce St
Philadelphia, PA 19104
Phone+1 215-615-0063

Fax+1 215-349-8144

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1999 - 2002
Rutgers Robert Wood Johnson Medical SchoolClass of 1999

Certifications & Licensure

PA State Medical License 2000 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer Start of enrollment: 2006 Aug 01
Completed
Phase 2
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer Start of enrollment: 2008 Jun 01
Withdrawn
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Treatment Preference and Patient Centered Prostate Cancer Care Start of enrollment: 2013 Jun 01
Completed
Not Applicable
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer Start of enrollment: 2021 Jul 01
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

55 citations
Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
Oliver Sartor, Nicholas J. Vogelzang, Christopher Sweeney, Daniel Celestino Fernandez, Fabio Almeida
The Oncologist. 2018-02-01
44 citations
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
Matthew Zibelman, Yu-Ning Wong, Karthik Devarajan, Lois Malizzia, Alycia Corrigan
Investigational New Drugs. 2015-06-20
428 citations
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
Nan Lin, Ann Vanderplas, Melissa E. Hughes, Richard L. Theriault, Stephen B. Edge
Cancer. 2012-11-15

Grant Support

Clinical And Social Implications Of COST Sharing For Cancer DrugsNational Cancer Institute2008–2011